VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BCPC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
BCPCBalchem Corporation
$169.21$5.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksBCPCFinancials

Balchem Corporation (BCPC) Financials

30Y historyFree accessUpdated daily

Balchem has successfully expanded its gross margin from 32.8% in 2023Q4 to 37.3% in 2026Q1, reflecting effective pricing power and cost management.

BCPC Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue1.06B1.04B953.68M922.44M942.36M799.02M703.64M643.71M643.68M594.79M553.2M552.49M541.38M337.17M310.39M291.87M255.07M219.44M232.05M176.2M100.91M839.1M67.41M61.88M60.2M46.14M33.2M29.7M28.7M28.6M26.4M
Revenue Growth %9.62%8.75%3.39%-2.11%17.94%13.55%9.31%0%8.22%7.52%0.13%2.05%60.57%8.63%6.35%14.43%16.24%-5.44%31.7%74.62%-87.97%1144.84%8.94%2.79%30.46%38.99%11.78%3.48%0.35%8.33%5.6%
Cost of Goods Sold673.8M666.53M617.48M620.38M661.91M555.85M479.75M432.34M439.43M405.78M372.34M384.39M397.21M239.75M220.85M205.87M177.03M152.48M179.47M129.27M66.9M54.41M43.6M40.72M36.89M28.22M17.14M15.6M15.6M15.3M13.7M
COGS % of Revenue-64.26%64.75%67.25%70.24%69.57%68.18%67.16%68.27%68.22%67.31%69.57%73.37%71.11%71.15%70.53%69.41%69.49%77.34%73.37%66.3%6.49%64.68%65.81%61.28%61.15%51.64%52.53%54.36%53.5%51.89%
Gross Profit383.55M370.63M336.21M302.06M280.45M243.17M223.9M211.37M204.25M189.01M180.86M168.1M144.17M97.42M89.54M86M78.04M66.96M52.58M46.93M34.01M784.68M23.81M21.15M23.31M17.93M16.06M14.1M13.1M13.3M12.7M
Gross Margin %36.27%35.74%35.25%32.75%29.76%30.43%31.82%32.84%31.73%31.78%32.69%30.43%26.63%28.89%28.85%29.47%30.59%30.51%22.66%26.63%33.7%93.52%35.32%34.19%38.72%38.85%48.36%47.47%45.64%46.5%48.11%
Gross Profit Growth %-10.24%11.31%7.7%15.33%8.61%5.93%3.48%8.06%4.51%7.59%16.59%47.99%8.8%4.11%10.21%16.55%27.35%12.03%38.01%-95.67%3196.14%12.55%-9.26%30.03%11.65%13.87%7.63%-1.5%4.72%3.25%
Operating Expenses161.83M152.3M153.3M142.86M135.26M115.67M112.75M108.81M96.5M91.75M90.02M74.14M62.03M31.82M29.76M29.78M28.27M26.3M23.23M21.02M14.84M11.78M11.01M12.14M11.13M9.77M8.1M9.1M8.3M9M9.6M
OpEx % of Revenue-14.68%16.07%15.49%14.35%14.48%16.02%16.9%14.99%15.43%16.27%13.42%11.46%9.44%9.59%10.2%11.08%11.98%10.01%11.93%14.71%1.4%16.33%19.62%18.48%21.18%24.41%30.64%28.92%31.47%36.36%
Selling, General & Admin150.37M142.8M136.5M130.13M123.07M102.15M102.42M97.44M84.91M82.45M82.7M68.15M57.22M28.2M26.34M26.89M25.08M23M20.35M18.51M12.82M9.72M9.26M10.05M9.22M8.14M7.03M5.8M5.6M6.8M7.4M
SG&A % of Revenue-13.77%14.31%14.11%13.06%12.78%14.56%15.14%13.19%13.86%14.95%12.34%10.57%8.36%8.49%9.21%9.83%10.48%8.77%10.51%12.71%1.16%13.73%16.25%15.31%17.64%21.19%19.53%19.51%23.78%28.03%
Research & Development24.92M18.51M16.79M15.05M12.19M13.52M10.33M11.38M11.59M9.3M7.33M5.99M4.81M3.62M3.42M2.89M3.19M3.3M2.88M2.51M2.02M2.05M1.75M2.08M1.91M1.63M1.07M1.3M1M1.1M800K
R&D % of Revenue-1.78%1.76%1.63%1.29%1.69%1.47%1.77%1.8%1.56%1.32%1.08%0.89%1.07%1.1%0.99%1.25%1.5%1.24%1.43%2%0.24%2.6%3.37%3.17%3.53%3.22%4.38%3.48%3.85%3.03%
Other Operating Expenses-362K-9.01M0-2.32M0000000-309K0-37K67K0000000000002M1.7M1.1M1.4M
Operating Income221.72M218.33M182.91M159.19M145.19M127.5M111.15M102.55M107.1M96.9M90.84M93.96M82.14M65.6M59.78M56.23M49.77M40.66M29.35M25.91M19.16M16.9M12.8M9.02M12.19M8.15M5.94M5M4.8M4.3M3.1M
Operating Margin %20.97%21.05%19.18%17.26%15.41%15.96%15.8%15.93%16.64%16.29%16.42%17.01%15.17%19.46%19.26%19.26%19.51%18.53%12.65%14.7%18.99%2.01%18.98%14.57%20.24%17.67%17.89%16.84%16.72%15.04%11.74%
Operating Income Growth %-19.37%14.9%9.65%13.87%14.71%8.38%-4.25%10.52%6.68%-3.32%14.38%25.21%9.74%6.32%12.97%22.41%38.54%13.29%35.19%13.36%32.09%41.95%-26.02%49.42%37.34%18.76%4.17%11.63%38.71%14.81%
EBITDA266.76M263.52M230.88M214.13M197.03M176.38M162.43M148.41M151.77M141.28M137.04M133.92M112.67M76.08M69.42M65.52M58.33M48.79M37.13M32.28M22.61M19.71M16.07M12.54M15.1M10.78M7.95M7M6.5M5.4M4.5M
EBITDA Margin %25.23%25.41%24.21%23.21%20.91%22.07%23.08%23.06%23.58%23.75%24.77%24.24%20.81%22.56%22.36%22.45%22.87%22.23%16%18.32%22.4%2.35%23.84%20.27%25.09%23.35%23.96%23.57%22.65%18.88%17.05%
EBITDA Growth %12.29%14.14%7.82%8.68%11.71%8.59%9.44%-2.21%7.42%3.1%2.33%18.86%48.1%9.59%5.96%12.32%19.55%31.39%15.03%42.8%14.69%22.68%28.13%-16.96%40.14%35.5%13.61%7.69%20.37%20%28.57%
D&A (Non-Cash Add-back)45.04M45.19M47.97M54.94M51.85M48.88M51.28M45.86M44.67M44.38M46.2M39.96M30.52M10.47M9.64M9.29M8.56M8.13M7.79M6.38M3.44M2.81M3.27M3.52M2.92M2.62M2.02M2M1.7M1.1M1.4M
EBIT158.38M209.25M182.98M159.87M144.02M127.69M110.86M102.44M106.64M96.02M90.19M93.66M82.2M65.84M59.85M56.82M50.22M40.81M29.39M25.91M19.16M16.9M12.8M9.02M12.19M8.15M5.94M5M4.8M4.3M3.1M
Net Interest Income-7.29M-10.22M-16.53M-22.61M-10.27M-2.46M-4.44M-5.96M-7.61M-7.53M-7.26M-6.58M-5.08M253K0100K199K-102K-856K000000000000
Interest Income00000000012K9K9K64K277K10K184K289K107K107K000000000000
Interest Expense10.4M10.22M16.53M22.61M10.27M2.46M4.44M5.96M7.61M7.54M7.26M6.59M5.14M24K10K84K90K209K963K000000000000
Other Income/Expense-18.1M-19.3M-16.46M-21.93M-11.44M-2.27M-4.73M-6.08M-8.07M-8.41M-7.9M-6.89M-5.09M216K67K513K361K-57K-917K-1.08M-61K288K-82K-252K-340K214K58K-100K-100K0-200K
Pretax Income203.61M199.03M166.45M137.26M133.75M125.23M106.42M96.48M99.03M88.49M82.93M87.06M77.05M65.82M59.84M56.74M50.13M40.6M28.43M24.83M19.1M17.19M12.71M8.76M11.85M8.37M6M4.9M4.7M4.3M2.9M
Pretax Margin %19.26%19.19%17.45%14.88%14.19%15.67%15.12%14.99%15.38%14.88%14.99%15.76%14.23%19.52%19.28%19.44%19.65%18.5%12.25%14.09%18.93%2.05%18.86%14.16%19.68%18.14%18.06%16.5%16.38%15.04%10.98%
Income Tax45.53M44.19M37.98M28.72M28.38M29.13M21.79M16.81M20.46M-1.58M26.96M27.34M24.23M20.94M19.84M17.97M16.85M13.82M9.38M8.71M6.82M6.24M4.69M3.13M4.43M3.26M2.27M1.8M1.7M1.5M1M
Effective Tax Rate %22.36%22.2%22.82%20.92%21.22%23.26%20.48%17.42%20.66%-1.79%32.51%31.4%31.44%31.82%33.15%31.68%33.62%34.03%33%35.08%35.72%36.28%36.88%35.66%37.39%38.94%37.81%36.73%36.17%34.88%34.48%
Net Income158.08M154.84M128.47M108.54M105.37M96.1M84.62M79.67M78.57M90.07M55.97M59.72M52.83M44.87M40.01M38.77M33.28M26.79M19.05M16.12M12.28M10.95M8.03M5.64M7.42M5.11M3.73M3.1M3M2.8M1.9M
Net Margin %14.95%14.93%13.47%11.77%11.18%12.03%12.03%12.38%12.21%15.14%10.12%10.81%9.76%13.31%12.89%13.28%13.05%12.21%8.21%9.15%12.17%1.31%11.91%9.11%12.32%11.07%11.23%10.44%10.45%9.79%7.2%
Net Income Growth %15.77%20.53%18.36%3.01%9.64%13.57%6.22%1.4%-12.77%60.92%-6.28%13.05%17.72%12.17%3.2%16.49%24.24%40.6%18.19%31.28%12.09%36.48%42.36%-23.98%45.13%37.03%20.29%3.33%7.14%47.37%18.75%
Net Income (Continuing)158.08M154.84M128.47M108.54M105.37M96.1M84.62M79.67M78.57M90.07M55.97M59.72M52.83M44.87M40.01M38.77M33.28M26.79M19.05M16.12M12.28M10.95M8.03M5.64M7.42M5.11M3.73M3.1M3M2.8M1.9M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)4.904.753.933.353.252.942.602.452.422.791.751.891.691.451.321.281.120.930.670.580.450.410.310.220.300.210.150.120.120.110.08
EPS Growth %16.79%20.87%17.31%3.08%10.54%13.08%6.12%1.24%-13.26%59.43%-7.41%11.83%16.55%9.85%3.13%14.29%20.43%38.81%15.52%28.89%9.76%32.26%40.91%-26.67%42.86%40%25%0%9.09%36.99%22.04%
EPS (Basic)-4.803.973.383.292.982.632.482.442.811.761.921.711.511.361.361.190.980.710.610.470.420.320.230.310.220.160.130.120.110.08
Diluted Shares Outstanding32.28M32.6M32.72M32.45M32.39M32.67M32.5M32.51M32.45M32.23M31.92M31.64M31.17M30.85M30.35M30.24M29.62M28.87M28.52M27.79M27.49M26.94M26.17M25.37M25.03M24.64M24.2M24.91M25.31M24.4M23.65M
Basic Shares Outstanding32.28M32.6M32.33M32.11M32.02M32.22M32.18M32.14M32.26M32.02M31.76M31.16M30.85M29.62M29.45M28.57M27.96M28.87M26.95M26.57M26.31M26.08M25.43M24.4M24.07M23.52M23.6M24.52M24.9M24.4M23.65M
Dividend Payout Ratio-18.27%19.91%21.07%19.66%19.48%19.74%19%17.09%13.4%19.15%15.49%14.87%-29.25%11.12%9.29%7.5%10.37%9.9%8.51%6.25%4.85%6.78%4.11%5.42%6.57%6.45%6.67%3.57%5.26%

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrong
Balance SheetFortress
Cash FlowRobust
Top Statement Risk

Ethylene Oxide Regulatory Exposure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Sustained Revenue Growth Momentum

According to recent financial disclosures, Balchem has demonstrated a consistent upward revenue trajectory, culminating in an 8.1% year-over-year increase in 2026Q1, which suggests that the company is successfully navigating complex macroeconomic conditions while maintaining its competitive positioning within the specialty chemical and nutritional ingredient markets.

The acceleration from negative growth in 2023Q4 to mid-single-digit and now high-single-digit growth indicates that the company's pricing power remains intact. Investors should monitor whether this growth is driven by volume expansion in core segments or if it remains heavily reliant on inflationary price pass-throughs.

Structural Margin Resilience and Expansion

As reported in quarterly filings, Balchem has successfully expanded its gross margin from 32.8% in 2023Q4 to 37.3% in 2026Q1, reflecting a robust ability to manage raw material input costs and maintain premium pricing for its specialized microencapsulation and chelation product offerings.

This margin expansion appears to validate the company's value-added strategy, distinguishing it from commodity-exposed peers. The ability to sustain these levels suggests that the company's proprietary technology provides a significant buffer against the volatility typically seen in petrochemical-derived input costs.

Operating Leverage Through Disciplined Scaling

Based on the provided income statement data, Balchem has effectively scaled its operating income from $38.3 million in 2023Q4 to $55.6 million in 2026Q1, indicating that the company is achieving meaningful operating leverage as revenue growth outpaces the expansion of its core operating expenses.

The company's ability to keep SG&A relatively contained while growing the top line suggests a lean operational structure. This efficiency warrants further investigation into whether future growth can be achieved without a proportional increase in overhead, which would further enhance bottom-line profitability.

Earnings Quality and Stock-Based Compensation

Analysis of recent income statements reveals that Balchem's net income growth has remained consistent, with 2026Q1 net income reaching $40.3 million, though investors should carefully evaluate the impact of stock-based compensation, which totaled $5.4 million in the most recent quarter, on overall earnings quality.

While the EPS growth trajectory appears strong, the periodic fluctuations in stock-based compensation suggest that management's incentive structures are a non-trivial component of the expense base. Analysts should consider whether these non-cash charges are appropriately aligned with long-term shareholder value creation or if they mask underlying operational costs.

Regulatory Risks to Margin Sustainability

Despite strong historical performance, the company faces significant potential headwinds as reported in recent regulatory filings, specifically regarding heightened EPA scrutiny of ethylene oxide emissions, which may necessitate substantial capital expenditures and threaten the long-term profitability of the Specialty Products segment's core sterilization operations.

Short-term margin stability may be misleading if the company is forced to incur significant compliance costs or face operational disruptions. Investors should monitor whether the current valuation adequately prices in the risk of a structural change to the regulatory environment governing its most profitable product lines.

BCPC — Frequently Asked Questions

Quick answers to the most common questions about buying BCPC stock.

What was Balchem Corporation's (BCPC) revenue in 2025?

For fiscal year 2025, Balchem Corporation (BCPC) reported total revenue of $1.04B. This represents a 3828.6% increase compared to $26.4M in 1996.

Is Balchem Corporation (BCPC) profitable?

Balchem Corporation (BCPC) is profitable, generating $154.8M in net income for the fiscal year ending 2025 with a net profit margin of 14.9%.

What is Balchem Corporation's operating profit margin?

Balchem Corporation (BCPC) reported an operating income of $218.3M, resulting in an operating profit margin of 21.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Balchem Corporation's gross profit and gross margin?

Balchem Corporation (BCPC) generated $370.6M in gross profit for the year, representing a gross profit margin of 35.7%. This demonstrates the company's core pricing power and production efficiency.